Preliminary Results/Change in ForecastBRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/2530-Apr-2025 / 17:54 ...

Cycuria aims to revolutionise treatment of hard-to-treat blood cancers with a first-in-class protein-based therapeutic approach specifically targeting both tumour cells and tumour stem cells·    ...

The Novo Nordisk Foundation today announced the latest edition of its annual Challenge Programme, where for the first time it is inviting researchers from outside Denmark, in the European Schengen ...

European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation ...

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans ...

Olon Group, a leading global pharmaceutical CDMO, announces the appointment of Jérôme Bédier as CEO of its French entities and Andrea Conforto as M&S VP CDMO of Olon Biotech, the division dedicated to ...

The Digital Poverty Alliance (DPA) has launched an inquiry into digital inclusion in the healthcare sector amid government announcements to allocate billions to digital transformation. At a time where ...

NCIMB Limited ("NCIMB"), a leading microbiology services provider and owner of the UK’s largest industrial, food and marine bacterial culture collection, has secured a £1.7m investment from the ...